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ABSTRACT 31 
A fluorescent nanoprobe is designed for the determination of carbamazepine (CBZ) in exhaled 32 
breath condensate (EBC) of patients receiving CBZ. The probe consists of copper nanoclusters 33 
(Cu NCs) coated with cetyl trimethylammonium bromide. The interaction of probe with CBZ 34 
results in blocking non-radiative e-/h+ recombination defect sites on the surface of Cu NCs and 35 
consequently enhancing the fluorescence intensity of Cu NCs. The experimental conditions were 36 
optimized by using a response surface methodology (central composite design). Under the 37 
optimized conditions, the calibration plot is linear in the 0.2 to 20 µg mL‒1 CBZ concentration 38 
range (excitation/emission wavelength: 290/480 nm) and the detection limit is as low as 0.08 µg 39 
mL‒1. The intra-day and inter-day relative standard deviations for six replicated measurements of 40 
10 µg mL–1 CBZ are 3.9 % and 4.8 %, respectively. The method was applied for the 41 
determination of CBZ level in EBC of patients receiving CBZ. The accuracy of the method was 42 
confirmed by HPLC-UV analysis as a references method. 43 
 44 
 45 
Keywords: Carbamazepine; Copper; Nanoprobe; Nanocluster; Fluorescence; Response 46 
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 48 
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 49 
1. Introduction  50 
Carbamazepine (5H-dibenzo [b,f] azepine-5-carboxamide, CBZ) is a carboxamide 51 
derivative of iminostilbene [1] and widely used for the therapy of patients with partial and 52 
generalized tonic-clonic epilepsy and psychiatric diseases [2]. So far, various methods, such as 53 
liquid chromatography–electrospray ionization mass spectrometry method (LC-EIA-MS) in 54 
serum samples [3], LC–MS-MS method in whole blood, serum and plasma [4], ion mobility 55 
spectrometry in formulation samples [5], stacking capillary electrophoresis method in serum 56 
samples [6], high-performance liquid chromatography-diode array detection assay after a simple 57 
sample preparation method by a packed sorbent  in plasma samples [7], online solid phase 58 
extraction - LC coupled with high resolution mass spectrum under targeted MS/MS analysis 59 
mode in serum sample [8], and a gas chromatography method [9] have been developed for the 60 
determination of CBZ. Although the advantages of such methods are undeniable, most of these 61 
techniques need a sample preparation procedure to remove matrix components or a derivatization 62 
step before analysis and also a labelled internal standard. So, development of an easy-to-use 63 
method that can be applied for off- and on-line determination of drugs concentrations in 64 
biological samples has always been of interest in bioanalytical and clinical applications. It is 65 
important to note that the assay of biomolecules should be fast, cost-effective, selective, and 66 
sensitive. For this purpose, increasing attention has been focused on the construction of 67 
fluorescent nanoprobes for drugs [10]. Quantum dots (QDs) and nanoclusters (NCs) with 68 
particular photophysical and photochemical properties, such as high luminescence intensity, 69 
stability and efficiency, narrow, and tunable spectrum according to their size and material 70 
composition, good solubility and biocompatibility, low toxicity, can offer significant advantages 71 
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for biosensing [11, 13]. However, to the best of our knowledge, QDs and/or NCs as an optical 72 
nanoprobe are rarely employed in the determination of CBZ and there is only one report in the 73 
literature for the detection of CBZ. Ma et al. [14] developed a fluorescent probe based on N-74 
doped carbon dots and used to the determination of CBZ in tablet and human urine spiked 75 
samples. They illustrated that the presence of CBZ in the range of 10‒90 µg mL‒1 result in 76 
fluorescence quenching of QDs. The detection limit was 1.93 µg mL‒1 [14]. 77 
Exhaled breath condensate (EBC) as a biological sample was chosen for this study since it 78 
possesses a number of advantages over other biological samples [15]. The collection of EBC, 79 
which has been used since the 1980s [16], are very simple and repeatable method without any 80 
side effect or any appreciable discomfort for the EBC sample donors [17]. EBC also have a few 81 
number of interfering compounds in compared with other matrices including blood, plasma, 82 
sputum, and urine [18]. Furthermore, the EBC collection can be repeated as often as required 83 
without any variation in the fluids on the lung surfaces [19]. The analysis of drugs in EBC is a 84 
promising process that has attracted a lot of attention [20-22].  85 
Herein, to continue our research works on EBC [20-22], we synthesize Cu NCs coated with 86 
cetyl trimethylammonium bromide (CTAB) and use them for the developing an effective 87 
nanoprobe with good selectivity and sensitivity for determination of CBZ level in EBC samples. 88 
Detection mechanism is based on the blocking non-radiative e-/h+ recombination defect sites on 89 
the surface of the NCs and improving the fluorescence intensity of NCs proportional with CBZ 90 
adding. For reaching better analytical figures of merit for the nanoprobe, the experimental 91 
conditions were investigated by response surface methodology (RSM), which employs statistical 92 
methods to present a second-order polynomial model between independent variables and a 93 
response variable.  94 
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 95 
2. Experimental     96 
2.1. Reagents and solutions 97 
All reagents were of analytical grade and ultrapure deionized water was obtained from 98 
Ghazi Pharmaceutical Co. (Tabriz, Iran, www.sgco-infusion.com) employed throughout the 99 
measurements. (Cu (NO3)2•3H2O, Sigma-Aldrich, www.sigmaaldrich.com), CTAB (C19H42BrN, 100 
Merck, www.merck.com), citric acid (C6H8O7•H2O, Merck) and hydrazine hydrate (H4N2.H2O, 101 
Sigma-Aldrich, www.sigmaaldrich.com) were used in the CuNCs synthesis procedure. Sodium 102 
chloride (NaCl, Scharlau, www.scharlab.com), potassium chloride (KCl, Merck), sodium sulfate 103 
(Na2SO4, Merck), aluminium nitrate (Al(NO3)3•9H2O, Merck), magnesium nitrate 104 
(Mg(NO3)2•6H2O, Chem-lab, www.chem-lab.be), sodium carbonate (Na2CO3, Merck), iron 105 
chloride (FeCl3•6H2O, Merck), calcium oxalate (CaC2O4•H2O, Carl. Roth GmbH & Co., 106 
www.carlroth.com/en/en), glucose (Merck), lamotrigine (Arastoo Pharmaceutical Company, Iran, 107 
www.arasto.com), sodium valproate (Temad Pharmaceutical Co., Iran, www.temad.com/fa), 108 
phenytoin (Amin Pharmaceutical Company, Iran, www.aminpharma.com) and phenobarbital 109 
(Pars Darou company, Iran, www.parsdarou.ir) were used in the interference study. A solution of 110 
1000 mg L−1 CBZ was prepared by dissolving a proper amount in methanol. Different 111 
concentrations of CBZ were prepared by diluting standard stock solutions with deionized water.  112 
 113 
2.2. Apparatus and software 114 
Fluorescence intensity were measured at 25 ˚C on a FP-750 spectrofluorometer (Jasco Corp., 115 
Japan, www.jasco.co.jp) with 20 nm band-pass in both of the excitation and emission paths and 116 
the sensitivity of medium. The instrument have a 150 W xenon lamp, dual monochromators, 1.0 117 
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cm quartz cell, Peltier thermostated single cell holder model ETC-272 (JASCO Corp., Japan), 118 
and supported with PC–based Windows® Spectra Manager TM software for JASCO 119 
Corporation. A double-beam UV–Vis spectrophotometer model UV-1800 (Shimadzu, Japan, 120 
www.shimadzu.com) with 1.0 cm quartz cells was used to record the UV–Vis absorption spectra. 121 
The pH adjustments of the used solutions were controled using a digital pH-meter model 744 122 
(Metrohm Ltd., Switzerland, www.metrohm.com) supplied with a glass-combined electrode. An 123 
ultrasonic bath (Alex machine, Istanbul) and An electronic analytical balance model AB204-S 124 
(Mettler Toledo, Switzerland, www.mt.com) was employed in this study. The shape and size of 125 
prepared QDs were characterized by a transmission electron microscopy model CM30 (Philips, 126 
The Netherlands, www.philips.com).  127 
Design and analysis of the central composite experiments were performed in MINITAB 128 
(Minitab Inc. Release 17.0, www.minitab.com/en-us/products/minitab) statistical package. 129 
 130 
2.3. Preparation of Cu NCs 131 
The Cu NCs were synthesized by following the method reprted in literature [23]. 10 mL of 2 132 
mol L–1 aqueous solution of hydrazine hydrate containing 0.5 mmol L–1 citric acid (0.05 mL 133 
citric acid of 0.1 mol L–1) and 5 mmol L–1 CTAB (0.0182 gr) were stirred for 30 min and added 134 
to 10 mL of 20 mmol L–1 solution of Cu(NO3)2.3H2O (0.0482 gr) containing 0.5 mmol L
–1 citric 135 
acid (0.05 mL citric acid of 0.1 mol L–1) and 5 mmol L–1 CTAB (0.0182 gr). The obtained 136 
mixture was agitated at room temperature for 3 h. (further details are given in the Electronic 137 
Supporting Material (ESM)) The prepared NCs were stored at 4°C in a dark place. The 138 
concentration of the prepared CuNCs solution was determined as 2.5 mg L–1 according to the 139 
flame atomic absorption spectroscopy used in the current study.  140 
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 141 
2.4. Sample preparation 142 
EBC samples were collected by a lab-made cooling trap system [24]. EBC samples used for 143 
method validation were a pool of samples collected from healthy subjects. EBC samples were 144 
directly analyzed without any pretreatment. Patient EBC samples were collected from four 145 
patients after oral administration of CBZ. Sample donors signed a consent form approved by the 146 
Ethics Committee of National Institute for Medical Research Development (approved No. IR 147 
NIMAD REC 1396 356).  148 
 149 
2.5. General procedure 150 
Fluorescence detection was made in a 2 mL vial by a batch method. In brief, 50 μL of 0.1 151 
mol L−1 phosphate buffer (pH 5.0), and 50 μL of 0.5 mg L−1 Cu-NCs were added into the vial. 152 
Afterwards, a proper volume of CBZ standard solution in the range of 0.2 to 20 µg mL‒1 was 153 
added and the volume was set in 0.5 mL with deionized water. To prevent a matrix effect on the 154 
validation data, EBC samples were used to validate the fluorimetric determination method. For 155 
this purpose, the EBC samples were collected from healthy subjects, spiked with proper aliquots 156 
of standard CBZ solution. After 10 min sonication, the fluorescence intensity was recorded at 157 
λem= 480 nm after excitation at 290 nm and used as an analytical signal.  158 
 159 
2.5. Real sample analysis  160 
EBC samples was obtained from four subjects who had taken CBZ. 0.25 mL of EBC samples 161 
directly (without any preparation) added into a 2 mL vial containing 50 μL of 0.1 mol L−1 162 
phosphate buffer (pH 5.0), and 50 μL of 0.5 mg L−1 Cu-NCs. The volume in vial was adjusted to 163 
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0.5 mL with deionized water. Then, the solution was equilibrated for 10 min in the sonication 164 
bathat room temperature. Finally, the obtained solution was transferred into microcell and the 165 
fluorescence intensity was measured at 480 nm after excitation at 290 nm. CBZ levels in EBC of 166 
patients were also analyzed using HPLC method described in the literature [25].  167 
 168 
3. Results and discussion 169 
3.1. Choice of nanoparticle’s type  170 
In order to investigate the nanoparticle’s type, various nanomaterials such as Cu NCs, Zn NCs, 171 
Ag NCs and carbon QDs (CQDs) were synthesized and used for determination of CBZ in a 172 
similar condition. Fluorescence spectra of these nanomaterials in the absence and presence of 173 
CBZ (10 µg mL‒1) are shown in Fig. 1S. As can be seen, Ag NCs, Zn NCs, CQDs do not any 174 
spectral changes in the presence of CBZ and only a slight interaction is observed between Cu 175 
NCs and CBZ. According to these results, in the next attempt, CTAB modified Cu NCs was used 176 
for production of an effective interaction between nanoparticles and CBZ due to non-ionic 177 
property of CBZ. The possible reason for such a large variation in fluorescence spectra of CTAB 178 
modified Cu NCs (Fig. 2S) is related to the incorporation of CBZ into the inner hydrophobic part 179 
of produced ad-micelles or hemi-micelles of CTAB on the surface of NCs and changing in 180 
environmental conditions of them that produce a suitable assemble and change the intrinsic 181 
fluorescence of nanoparticles.  182 
 183 
3.2. Characterization of Cu-NCs 184 
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The shape and size of synthesized NCs were characterized by transmission electron 185 
microscopy (TEM). As can be seen in Fig. 1, the NCs are uniform in size and exhibit a nearly 186 
spherical shape with an average size of <8 nm.  187 
(Fig. 1 here) 188 
3.3. Detection mechanism discussion 189 
In the high concentration of prepared NCs and under single wavelength excitation at 290 nm, the 190 
Cu-NCs shows two fluorescent bands centred at 415 and 480 nm (Fig. 2). According to previous 191 
studies, the dual fluorescent bands of the QDs can be attributed to different surface states [26]. It 192 
should be noted that the low concentration of NCs was used for detection of CBZ; thus, in the 193 
absence of CBZ, the synthesized NCs emits only a well-resolved emission peak at 415 nm. Upon 194 
the addition of CBZ, the fluorescence spectra show a new emission peak centred at 480 nm, 195 
whereas the intensity at 415 nm of the NCs remains relatively unchanged. The fluorescence 196 
spectra of the designed nanoprobe after addition of various concentration of CBZ is shown in 197 
Fig. 3. As can be seen, the fluorescence intensity is proportional to the amount of CBZ, ranging 198 
from 0.2 to 20 µg mL‒1, which can be used for the quantification of CBZ.  199 
Two classes of fluorescence emission mechanisms have been reported for QDs and/or NCs in the 200 
literature: (i) the bandgap transitions; (ii) transitions arising from surface defects in QDs; 201 
generally any sites that result in surface energy traps [27]. Surface modification of QDs and 202 
interaction with surrounding species may change their chemical and optical properties [28, 29] 203 
and cause to some effects including: (i) activation of fluorescence by enhancement of excitonic 204 
and defect emission by blocking non-radiative electron/ hole (e-/h+) recombination defect sites on 205 
the surface of the QDs, (ii) creation of new traps on the surface of the QDs causing appearance 206 
of new emission peaks, (iii) enhancement of the selectivity and efficiency of light-induced 207 
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reactions done on the surface of QDs [30], (iv) it may quench QDs fluorescence through two 208 
possible pathways: fluorescence resonance energy transfer (FRET) and the common charge 209 
transfer [31]. 210 
In this study, CTAB was grafted on the Cu-NCs surface and served as the linking reagent for 211 
linking of CBZ. We conjectured that the interaction of Cu-NCs with CBZ resulted in blocking 212 
non-radiative e-/h+ recombination defect sites on the NCs surface and consequently enhancing 213 
the fluorescence intensity of NCs.                214 
 (Fig. 2 and 3 here) 215 
3.4. Optimization of reaction conditions by a central composite design (CCD)  216 
RSM was used to investigate the influence of several reaction factors that affect the 217 
determination of CBZ by considering the interactive effects of independent factors (pH, the 218 
probe and phosphate buffer concentration, and the reaction time of the system, in this case). 219 
Respective data and figures are given in ESM. The optimum values obtained for each 220 
investigated variable to reach the maximum signal intensity are: pH 6.0, [phosphate buffer]=16.5 221 
mmol L−1, [Cu-NCs]= 0.05 mg L−1, and time = 10 min. 222 
 223 
3.5. Interferences study 224 
The selectivity of the nanoprobe toward analyte in the presence of various anions, cations 225 
and possible co-administered drugs is also investigated by measuring the fluorescence intensity 226 
upon the addition of various concentrations of interferents. From a practical viewpoint, CBZ is 227 
used as a single drug the treatment of most forms of epilepsy and the drug of first choice in the 228 
germinal neural-gia [32] and as a combined drug regimen in bipolar mania, restless legs 229 
syndrome and schizophrenia [33]. The most frequently co-prescribed drugs with CBZ include 230 
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the antiepileptic drugs and we tested the interference of available antiepileptic drugs in this work. 231 
The results are presented in Table 1. The results show that the presence of anions and cations, 232 
such as Na+, Cl–, SO4
2–, K+ and Ca2+ do not affect the fluorescence intensity of the nanoprobe. 233 
The tolerance concentrations of other substances (with the exception of Fe3+ and lamotrigine) 234 
when determination 10 µg.mL-1 of CBZ by employing the nanoprobe are at least 10 times higher 235 
than that of CBZ. However, the amounts of lamotrigine in EBC samples are reported to be in the 236 
range of 0.5 ‒ 0.7 µg.mL-1 [21] which are below its tolerable level. So, there would be no 237 
interference from it in CBZ determination in EBC samples.  238 
(Tables 1 here) 239 
In addition, patients receiving CBZ, may take some non-prescribed over-the-counter drugs 240 
such as pain killers etc. The interference of these drugs were also investigated. But this time 241 
according to detection range founded for CBZ in EBC (0.3 ‒ 0.5 µg.mL-1), interference studies 242 
were performed for CBZ concentration of 0.5 µg.mL-1. The results are shown in Table 2. As can 243 
be seen naproxen, chlordiazepoxide, glibenclamide, oxazepam, acetaminophen, celecoxib, and 244 
clonazepam interfere with CBZ determination when they are present in 25 times of the 245 
concentration rations of interfering substance to CBZ. It means that interfering concentration for 246 
these drugs is about 12.5 µg.mL-1 which is much higher than concentration founded for the drugs 247 
in EBC. As limited data are published for concentration range of drugs in EBC samples, we 248 
checked this claim for a safe drug e.g. acetaminophen. For this purpose, a healthy volunteer is 249 
given 1 g of acetaminophen daily for 3 days. After this time, the concentration of acetaminophen 250 
in EBC of investigated subject is found to be < 0.1 µg.mL-1 which is below its tolerable level. 251 
These results demonstrate that the presented nanoprobe has good selectivity for CBZ detection. 252 
(Tables 2 here) 253 
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3.6. Analytical figures of merit 254 
In the optimum conditions described, a linear relationship (R2 =0.993) between the CBZ 255 
concentration and fluorescence intensity was observed at the concentration range of 0.2−20 µg 256 
mL−1 (excitation/emission wavelength: 290/480 nm). The regression equation was ΔIF = 21.626 257 
CCBZ + 18.691, where ΔIF is the response intensity difference between blank (nanoprobe in the 258 
absence of CBZ) and sample solution (nanoprobe in the presence of CBZ) in an arbitrary unit, 259 
and CCBZ is the concentration of CBZ in µg mL
−1 (Fig. 4). The detection limit of the present 260 
method for CBZ determination was computed after the employig of the mentioned general 261 
procedure for blank solutions. The detection limit and quantification limit, defined as 3 Sb/m, and 262 
10 Sb/m (where Sb is the standard deviation of the blank and m is the slope of the calibration plot) 263 
are 0.08 µg mL–1 and 0.20 µg mL–1, respectively. The precision of the method was investigated 264 
by replicating the CBZ determination during the course of experimentation on different days and 265 
on the same day. The intra-day and inter-day relative standard deviations (%RSD) for six 266 
replicated measurements of 10 µg mL–1 CBZ are 3.9 % and 4.8 %, respectively. Furthermore, the 267 
influence of Cu-NCs got from different batches on the analytical response was also investigated. 268 
The %RSD (n = 3) from fluorescence signals was 5.2 %, demonstrating the good batch-to-batch 269 
reproducibility of the synthesized NCs. A comparison of our method with some other published 270 
methods for determination of CBZ is shown in Table 3. As can be seen, the LOD of method is 271 
good and comparable with that of other reported methods. Also, the method is relatively rapid 272 
due to direct analysis and no need for any sample preparation procedure prior to analysis. 273 
Whereas, most of reported method applied for determination of CBZ used a liquid or solid-phase 274 
extraction for cleanup and analyte preconcentration before the sample analysis. These results 275 
show that the presented nanoprobe has good performance for CBZ determination. However, 276 
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there are some issues related to the used nanoprobe and EBC which limit their application. These 277 
issues include (i) poor storage stability of nanoprobe over longer periods of time due to their 278 
small size (with an average size of <8 nm) and large surface area which can lead to particle-279 
particle aggregation and making physical handling of nanoparticles difficult in liquid form; and 280 
(ii) some limitations associated with the EBC samples including adsorption of analytes to the 281 
surface of the collection setup, patient-to-patient variability in EBC volume and the effect of 282 
lung function on the collected sample volume and unavailability of an accepted dilution marker 283 
for EBC samples. These limitations and some solutions to overcome them are discussed in 284 
reference [15] in details.  285 
(Fig. 4 here) 286 
(Table 3 here) 287 
3.7. EBC sample analysis 288 
To further investigate the applicability of the nanoprobe on real samples, the probe was used 289 
to detect CBZ in EBC of patients receiving CBZ. All samples were taken 1 h after taking the last 290 
dose. The results of the analysis are summarized in Table 4. The accuracy of the method was 291 
approved by HPLC measurement as a reference method applied on a same EBC sample [34]. 292 
Using the paired t-test (2-tail) shows no significant difference at 95% confidence level 293 
demonstrating the method is accurate and has a great potential for determination of CBZ in EBC 294 
samples. 295 
(Table 4 here) 296 
4. Conclusions 297 
In this study, a sensitive nanoprobe for CBZ determination has been developed. The 298 
nanoprobe takes advantage of the high sensitivity and the high stability of the CTAB-coated NCs 299 
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toward CBZ to provide an effective platform for reliable determination of CBZ. The nanoprobe 300 
was successfully used for the determination of CBZ in EBC of patients receiving CBZ and an 301 
average level of 0.47 µg mL−1 was reported. Reliability and no practical limitation of the method 302 
makes it a promising system for routine quantification of CBZ in clinical practices. This is the 303 
first report on CBZ levels in EBC and these types of CBZ quantifications using a non-invasive 304 
sampling method are highly in demand in dosage adjustment of CBZ.  305 
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 401 
 402 
Fig. 1. TEM image CTAB coated Cu-NCs. 403 
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 406 
 407 
Fig. 2. Excitation and emission spectrum of CTAB coated Cu NCs 408 
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 409 
 410 
 411 
Fig. 3. Fluorescence spectrum of the CTAB coated Cu NCs in the absence (a) and presence of CBZ 412 
in the concentration range of 0.2–20 µg mL−1 (b-h). Conditions: pH 6, [phosphate buffer]=16.5 mmol L−1, 413 
[Cu-NCs]= 0.05 mg L−1, and time = 10 min, λex/λem: 290/ 480 nm. 414 
 415 
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Fig. 4. Fluorescence intensity difference (ΔIF) of CTAB coated Cu NCs in the absence and presence 
of CBZ versus CBZ concentration in the range of 0.2–20 µg mL−1. Conditions: pH 6, [phosphate 
buffer]=16.5 mmol L−1, [Cu-NCs]= 0.05 mg L−1, and time = 10 min, λex/λem: 290/ 480 nm. 
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Table 1 
Tolerance limits of interfering substances (commonly existing compounds in biological samples, co-
prescribed drugs) in the determination of 10 µg mL−1 of CBZ. 
 
 
Interfering substances  Tolerance limit 
Na+, Cl–, SO4–2 1000 
K+ 700 
Oxalate 500 
Ca+2, Glucose,  Sucrose 200 
Mg2+, CO32–,  Sodium valproate 100 
Al3+, Phenobarbital, Phenytoin, Topiramate 10 
Fe3+, Lamotrigine 1 
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Table 2 
Tolerance limits of some co-administrated and over-the-counter drugs in the determination of 0.5 µg 
mL−1 of CBZ. 
 
 
 
 
Interfering substances  Tolerance limit 
Cetirizine 500 
Sitagliptin, Dextromethorphan 200 
Nifedipine, Amiloride, Amoxicillin, Alprazolam, Lovastatin, Metoprolol, 
Nicotinamide, Ibuprofen, Pantoprazole, Diltiazem, Diazepam, Salicylic acid 
100 
Naproxen, Chlordiazepoxide, Glibenclamide, Oxazepam, Acetaminophen, 
Celecoxib, Clonazepam 
25 
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Table 3 
Comparison of analytical characteristics of the presented method with other reported techniques for determination of CBZ. 
Method 
Clean up/Pre-concentration 
method 
Real sample 
Linear range 
(µg mL−1) 
LOD 
(µg mL−1) 
Reference 
LC-EIA-MSa Protein precipitation extraction Serum  0.5 ‒ 20 ‒ [3] 
LC–MS-MS Protein precipitation extraction Whole blood, 
serum and plasma 
0.5 ‒ 50 0.25 [4] 
Ion mobility spectrometry DLLMEb Formulation 
samples 
0.05 ‒ 10 0.025 [5] 
SCEc-UV LLEd Serum 0.03 ‒ 25 0.01 [6] 
HPLC-DADe MEPSf Plasma 0.1 ‒ 15 ‒ [7] 
N-doped carbon dots based 
fluorescent probe  
‒ Tablet and human 
urine 
10‒90  1.93  [14] 
CTAB coated Cu NCs-based 
fluorimetric assay 
‒ EBC 0.2  – 20 0.08 This work 
a Liquid chromatography–electrospray mass spectrometry 
b Dispersive liquid–liquid microextraction 
c Stacking capillary electrophoresis 
d Liquid–liquid extraction 
e High-performance liquid chromatography–diode-array 
f Microextraction by packed sorbent 
g High resolution mass spectrum 
h Solid phase extraction 
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Table 4 
Details of the real samples and found concentration of CBZ by our method and HPLC method in the EBC samples of patients treated with CBZ 
 
No. Gender Age (year) 
Daily dosage 
(mg) 
CBZ level in EBC (µg mL–1) 
t-valueb 
Present methoda References methoda 
1 Female 32 500  0.51 ± 0.02 0.52 ± 0.04 0.625 
2 Male 61 400  0.39 ± 0.05 0.42 ± 0.01 1.11 
3 Male 39 600  NDc ND ‒ 
4 Female 19 800  0.50 ± 0.02 0.55 ± 0.08 1.14 
aThe found values are the averages of three determinations ± standard deviation in μg mL-1. 
 bCritical t-value is 4.30. 
c Not detected.  
 
 
 
 
 
